Literature DB >> 7963786

The use of chlorpromazine for symptom control in dying cancer patients.

B McIver1, D Walsh, K Nelson.   

Abstract

Terminal restlessness is a significant problem in deaths from advanced cancer, it is difficult not only for patients, but for family and health-care providers also. Chlorpromazine is an antipsychotic phenothiazine, safe at high doses and by many routes. It has also been used as an adjunct to morphine in advanced cancer. We have conducted a study using chlorpromazine in 20 patients, in which the drug was administered intravenously (i.v.) or rectally (PR) in inpatients and outpatients for terminal restlessness and dyspnea. The median PR dose was 25 mg every 4-12 hr. The median IV dose was 12.5 mg every 4-12 hr. Eighteen patients had complete relief and two had partial relief before death. We find chlorpromazine safe and effective for the relief of terminal restlessness and dyspnea in advanced cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963786     DOI: 10.1016/0885-3924(94)90193-7

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  10 in total

Review 1.  Practical guide to palliative sedation.

Authors:  John D Cowan; Teresa W Palmer
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

2.  Efficacy and safety of deep, continuous palliative sedation at home: a retrospective, single-institution study.

Authors:  Giampiero Porzio; Federica Aielli; Lucilla Verna; Giovanna Micolucci; Paolo Aloisi; Corrado Ficorella
Journal:  Support Care Cancer       Date:  2009-04-03       Impact factor: 3.603

Review 3.  Management of refractory breathlessness in patients with advanced cancer.

Authors:  Steffen T Simon; Claudia Bausewein
Journal:  Wien Med Wochenschr       Date:  2009-12

Review 4.  The dying patient.

Authors:  J D Cowan
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

5.  Patient and/or family controlled palliative sedation with midazolam for intractable symptom control: a case series.

Authors:  Diamanto Aretha; Eleftheria S Panteli; Panagiotis Kiekkas; Menelaos Karanikolas
Journal:  Cases J       Date:  2009-02-11

6.  Use of palliative sedation for intractable symptoms in the palliative care unit of a comprehensive cancer center.

Authors:  Ahmed Elsayem; Eardie Curry Iii; Jeanette Boohene; Mark F Munsell; Bianca Calderon; Frank Hung; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2008-05-07       Impact factor: 3.603

Review 7.  Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults.

Authors:  Steffen T Simon; Irene J Higginson; Sara Booth; Richard Harding; Vera Weingärtner; Claudia Bausewein
Journal:  Cochrane Database Syst Rev       Date:  2016-10-20

8.  Development of a FLIPR assay for the simultaneous identification of MrgD agonists and antagonists from a single screen.

Authors:  Seena K Ajit; Mark H Pausch; Jeffrey D Kennedy; Edward J Kaftan
Journal:  J Biomed Biotechnol       Date:  2010-09-14

9.  Ensuring competency in end-of-life care: controlling symptoms.

Authors:  Frank D Ferris; Charles F Von Gunten; Linda L Emanuel
Journal:  BMC Palliat Care       Date:  2002-07-30       Impact factor: 3.234

10.  New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells.

Authors:  Jörg C Heinrich; Sainitin Donakonda; V Joachim Haupt; Petra Lennig; Yixin Zhang; Michael Schroeder
Journal:  Oncotarget       Date:  2016-10-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.